PARIS (Reuters) - Ipsen said two late-stage clinical trials for its experimental hemophilia drug have been put on hold, potentially delaying the French drugmaker's entry into the blood disorders market by up to six months. The setback sent Ipsen shares down 11.3 percent at 17.72 euros by 1001 GMT - the worst performer on the French SBF 120 index - while the index was up 1.1 percent. Ipsen said a high percentage of patients in the trials developed antibodies to a protein used to make the bleeding disorder treatment, which it had hoped to launch in the first half of 2013. ...
via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment